Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK To Maintain Avandia Sales Rep Totals After Bristol Copromotion Ends

Executive Summary

GlaxoSmithKline will continue to support the anti-diabetic Avandia with 2000 sales reps after a copromotion agreement with Bristol-Myers Squibb ends Aug. 20

You may also be interested in...



GSK Avandamet Antidiabetic Combo Expected In Pharmacies In November

GlaxoSmithKline's Avandamet combination rosiglitazone/metformin product for diabetes is expected to be available in November, the company said after Oct. 10 FDA approval

GSK Avandamet Antidiabetic Combo Expected In Pharmacies In November

GlaxoSmithKline's Avandamet combination rosiglitazone/metformin product for diabetes is expected to be available in November, the company said after Oct. 10 FDA approval

From The Quarterly Conference Calls

Geneva Augmentin generic reserve: Geneva's generic amoxicillin/clavulanate earnings are being placed in a reserve in the event the company loses GlaxoSmithKline's appeal of the Augmentin patent lawsuit, Novartis CEO Daniel Vasella said July 22. "We will book sales, but we will not book the earnings out of this product but put them in a reserve," the exec said. "The additional exposure should we - against all odds - lose the appeal next year, would be an amount which we can digest, I would say, rather easily." GSK is appealing a May 22 ruling in Geneva's favor; a decision could come as early as January (1"The Pink Sheet" May 27, p. 20). Geneva launched amoxicillin generics in June...

Related Content

UsernamePublicRestriction

Register

PS040304

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel